NASDAQ
1.30USD
-0.14 (-9.72%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
403.8M
P/E
—
EPS
—
Beta
2.29
52W range
1.09-2.73
Day range
1.27–1.47
Open
1.43
Prev close
1.44
Volume
11.5M
Avg volume
6.3M
Dividend
0.00
IPO
2010-10-27
https://seekingalpha.com/article/4931448-pacific-biosciences-q2-its-only-getting-worse-reiterate-sell · 8/6/2026-0.90
https://www.zacks.com/stock/news/2956817/here-s-why-pacific-biosciences-of-california-pacb-fell-more-than-broader-market?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v3-2956817 · 7/20/2026-0.30
https://www.zacks.com/stock/news/2948972/pacific-biosciences-of-california-pacb-stock-drops-despite-market-gains-important-facts-to-note?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v3-2948972 · 7/6/2026+0.40
https://www.zacks.com/stock/news/2936899/pacific-biosciences-of-california-pacb-stock-sinks-as-market-gains-here-s-why?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v3-2936899 · 6/12/2026-0.20
https://www.zacks.com/stock/news/2931882/here-s-why-you-should-add-pacbio-stock-to-your-portfolio-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|rank_focused-2931882 · 6/3/2026+0.60
https://www.zacks.com/stock/news/2915002/pacbio-pre-q1-analysis-time-to-buy-hold-or-sell-the-stock-now?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2915002 · 5/5/2026+0.60
https://www.zacks.com/stock/news/2901075/why-pacific-biosciences-of-california-pacb-outpaced-the-stock-market-today · 4/15/2026+0.60
https://www.globenewswire.com/news-release/2026/04/15/3274525/16261/en/PacBio-and-Covaris-Announce-Joint-Workflow-Enabling-HiFi-Long-Read-Sequencing-of-FFPE-Tumor-Samples.html · 4/15/2026+0.80
https://www.zacks.com/stock/news/2896040/pacific-biosciences-of-california-pacb-laps-the-stock-market-here-s-why · 4/7/2026+0.60
https://www.zacks.com/stock/news/2891230/pacific-biosciences-of-california-pacb-registers-a-bigger-fall-than-the-market-important-facts-to-note?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6v3-2891230 · 3/27/2026-0.40
https://www.zacks.com/stock/news/2890079/pacbio-wins-basecamp-research-deal-for-trillion-gene-atlas-initiative?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2890079 · 3/26/2026+0.80
https://www.prnewswire.com/news-releases/ultima-genomics-announces-ug200-series-selected-for-basecamp-researchs-groundbreaking-trillion-gene-atlas-302719317.html · 3/19/2026+0.50
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works